RBC Downgrades Sage (SAGE) to Underperform, 'Too Much Riding On Dalza Huntington's Readout Our Analysis Shows Is High Risk'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams downgraded Sage Therapeutics (NASDAQ: SAGE) from to Underperform with a price target of $4.00.The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
